WASHINGTON, July 21 — When a patient’s doctor chooses one treatment over another, the decision rarely rests on clinical results alone. Cost-effectiveness analysis (CEA) — a form of economic analysis that compares the relative costs and outcomes of different courses of action — is increasingly shaping those choices, especially in health care systems where resources are finite. The method is distinct from cost–benefit analysis, which assigns a monetary value to the measure of effect.
In health services, monetizing health effects — a year of life, a premature birth averted, an additional year of sight — can feel inappropriate. CEA instead expresses itself as a ratio: the denominator is a gain in health from a measure, and the numerator is the cost associated with that gain.
The most commonly used outcome measure is the quality-adjusted life year, or QALY, which combines length and quality of life into a single metric.
What Is Cost-Effectiveness Analysis?
A special case of CEA known as cost–utility analysis measures effects in terms of years of full health lived, using QALYs or disability-adjusted life years (DALYs). The incremental cost-effectiveness ratio, or ICER, captures the change in costs relative to the change in effects — the extra cost to obtain one more unit of health. Analysts often visualize these trade-offs on a four-quadrant plane, with cost on one axis and effectiveness on the other.
Distributional cost-effectiveness analysis extends the core methods to incorporate concerns for how outcomes are spread across a population, not just their average level. That makes trade-offs between equity and efficiency explicit, a critical dimension for interventions designed to tackle health inequality.
In pharmacoeconomics, the cost-effectiveness of a therapeutic or preventive intervention is expressed as the ratio of its cost — usually in monetary terms — to a relevant measure of effect. That effect might be the number of people cured of a disease, the reduction in diastolic blood pressure, or the number of symptom-free days gained. Non-monetary factors such as side effects, influence on other prescriptions, or even minor convenience considerations may also be weighed.
The selection of the appropriate effect measure depends on clinical judgment in the context of the specific intervention. A complete compilation of cost-utility analyses exists in peer-reviewed medical and public health literature, offering clinicians and policymakers a growing evidence base for decisions that affect millions of people.
Beyond the Hospital: CEA in Other Fields
Cost-effectiveness analysis is not limited to health. In military acquisitions, competing tank designs are compared not only by purchase price but also by operating radius, top speed, rate of fire, armor protection, and gun caliber and penetration. A tank with equal or slightly inferior performance but substantially lower cost and easier production may be selected as more cost-effective.
Conversely, if the price difference between two tanks is near zero but the costlier one offers an enormous battlefield advantage — such as special ammunition, radar fire control, or laser range finding — planners may choose it based on the same principle. The parallel is instructive.
Whether in a hospital formulary committee or a defense procurement office, CEA provides a structured framework for deciding where limited resources can do the most good for the most people. For those developing new therapies, understanding these ratios is essential to demonstrating value. And for the public, the method offers transparency: it forces decision-makers to explain not just what works, but at what cost and for what gain.
As health systems worldwide face rising costs and aging populations, the human purpose behind the numbers — to stretch every dollar toward the greatest possible health benefit — remains the quiet engine behind the analysis. Consult your doctor for medical advice.
—
